Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PAX3 | P23760 | 1/20 | 0.37 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.37 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219477 | 0.84 | GDA (0.62) | GDAKDM4EGAATSHRALDH1A1 | |
| SCHEMBL16573451 | 0.80 | SMN1; SMN2 (0.59) | GDAKDM4EGAATSHRALDH1A1 | |
| SCHEMBL12227604 | 0.80 | GDA (0.45) | GDAKDM4EGAATSHRALDH1A1 | |
| SCHEMBL12227605 | 0.79 | TSHR (0.44) | GDATSHRALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL23892053 | 0.79 | KDM4E (0.48) | GDAKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL766668 | 0.79 | HPGD (0.46) | GDAKDM4EGAAALDH1A1HPGD | |
| SCHEMBL29259943 | 0.79 | NOS1 (0.40) | NOS1GDAKDM4EGAATSHR | |
| SCHEMBL735411 | 0.79 | GDA (0.72) | GDAPNP | |
| SCHEMBL1398291 | 0.77 | GDA (0.42) | GDAKDM4EGAAALDH1A1HPGD | |
| SCHEMBL23507659 | 0.77 | TSHR (0.36) | KDM4ETSHRHSD17B10PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1757 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| US-12428441-B2 | Modified nucleoside phosphoramidites | Janssen Biopharma, Inc. (US) | 2025-09-30 | — | — | US | claimed |
| EP-4606903-A1 | METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEOSIDE CONTAINING PROTECTING GROUP, AND COMPOSITION | Asymchem Life Science (Tianjin) Co., Ltd (CN) | 2025-08-27 | — | — | EP | claimed |
| US-20240309040-A1 | Modified Nucleoside Phosphoramidites | Janssen Biopharma, Inc. (US) | 2024-09-19 | — | — | US | claimed |
| US-12030907-B2 | Modified nucleoside phosphoramidites | Janssen Biopharma, Inc. (US) | 2024-07-09 | — | — | US | claimed |
| US-11987599-B2 | Solid support for synthesizing nucleic acid sequences and methods for making and using | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-05-21 | — | — | US | claimed |
| WO-2024082545-A1 | METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEOSIDE CONTAINING PROTECTING GROUP, AND COMPOSITION | 凯莱英生命科学技术(天津)有限公司 | 2024-04-25 | — | — | WO | claimed |
| CN-117343111-B | Preparation method of nucleoside modifier N2-isobutyryl-2' -methoxy guanosine | 康羽生命科学技术(苏州)有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-117343111-A | Preparation method of nucleoside modifier N2-isobutyryl-2' -methoxy guanosine | 康羽生命科学技术(苏州)有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-114014902-B | Dimeric nucleotide and synthesis method thereof | 上海兆维科技发展有限公司 | 2023-12-01 | — | — | CN | claimed |
| EP-0679657-A2 | Nucleosides and oligonucleotides containing 2'-ether groups | CIBA-GEIGY AG (CH) | 1995-11-02 | — | — | EP | claimed |
| WO-1995020597-A1 | MODIFIED OLIGONUCLEOTIDES | CIBA-GEIGY AG (CH) | 1995-08-03 | — | — | WO | claimed |
| WO-1995018139-A1 | SYNTHESIS OF PROPARGYL MODIFIED NUCLEOSIDES AND PHOSPHORAMIDITES AND THEIR INCORPORATION INTO DEFINED SEQUENCE OLIGONUCLEOTIDES | CHEMGENES CORPORATION (US) | 1995-07-06 | — | — | WO | claimed |
| CN-1100728-A | Nucleosides and oligonucleotides having 2'-ether groups | CIBA GEIGY AG (CH) | 1995-03-29 | — | — | CN | claimed |
| EP-0644196-A1 | TTTr as a protecting group in nucleotide synthesis | CIBA-GEIGY AG (CH) | 1995-03-22 | — | — | EP | claimed |
| EP-0626387-A1 | Nucleosides and oligonucleotides with 2'-ether groups | CIBA-GEIGY AG (CH) | 1994-11-30 | — | — | EP | claimed |
| EP-0612994-A2 | Matrix for matrix-assisted laser desorption mass spectroscopy | CIBA-GEIGY AG (CH) | 1994-08-31 | — | — | EP | claimed |
| US-5332814-A | Process for the preparation of carbacyclic nucleosides, and intermediates | CIBA-GEIGY CORPORATION (US) | 1994-07-26 | — | — | US | claimed |
| EP-0577558-A2 | Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates | CIBA-GEIGY AG (CH) | 1994-01-05 | — | — | EP | claimed |
| EP-0542681-A1 | Process for the preparation of carbocyclic nucleosides and its intermediates | CIBA-GEIGY AG (CH) | 1993-05-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030907-B2 | Modified nucleoside phosphoramidites | PNP, TYMP, NSUN2 | NOS1 3613/4885GDA 92/4885KDM4E 2370/4885 |
| US-12428441-B2 | Modified nucleoside phosphoramidites | MTAP, PNP, NT5C3B | NOS1 2988/4885GDA 72/4885KDM4E 3283/4885 |
| US-11987599-B2 | Solid support for synthesizing nucleic acid sequences and methods for making and using | RNGTT, NSUN2, POLN | NOS1 1578/4885GDA 264/4885KDM4E 1416/4885 |
| US-20240309040-A1 | Modified Nucleoside Phosphoramidites | MTAP, PNP, NT5C3B | NOS1 2988/4885GDA 72/4885KDM4E 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.